Disinvestment is always a challenge, and it continues to be. However, the kinds of analyses and health technology assessments that have been conducted by CADTH, which are shared with the provincial jurisdictions, provide the jurisdictions with some effectiveness studies they can base their policy decisions on. So it's a beginning, and it's a way to start using better evidence to inform decisions around what should be on the formulary and what should come off.
On May 6th, 2008. See this statement in context.